Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly

Hamide Piskinpasa; Yildiz Okuturlar; Sema Ciftci Dogansen; Yasemin Sefika Akdeniz; Ayse Esen; Sogol Sadri; Osman Pirhan; Aysegul Akdogan Gemici; Sibel Ocak Serin; Asuman Gedikbası; Mine Adas; Meral Mert

doi:10.1055/a-0998-4079

Hormone and Metabolic Research, Inhaltsverzeichnis

Horm Metab Res 2019; 51(10): 649-654
DOI: 10.1055/a-0998-4079

Endocrine Care

Visfatin Levels May be an Early Marker of Atherosclerosis in Patients with Acromegaly

Hamide Piskinpasa

¹Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Yildiz Okuturlar

²Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Sema Ciftci Dogansen

¹Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Yasemin Sefika Akdeniz

¹Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Ayse Esen

¹Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Sogol Sadri

²Department of Internal Medicine, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Osman Pirhan

³Department of Cardiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Aysegul Akdogan Gemici

⁴Department of Radiology, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Sibel Ocak Serin

⁵Department of Internal Medicine, Umraniye Training and Research Hospital, Istanbul, Turkey

,

Asuman Gedikbası

⁶Department of Biochemistry, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

,

Mine Adas

⁷Department of Internal Medicine, Okmeydani Training and Research Hospital, Istanbul, Turkey

,

Meral Mert

¹Department of Endocrinology and Metabolism, Bakirkoy Dr. Sadi Konuk Training and Research Hospital, Istanbul, Turkey

› Institutsangaben

Abstract

The purpose of the study was to compare serum visfatin levels between patients with acromegaly and healthy controls and to evaluate the relationships between visfatin levels and epicardial fat thickness (EFT), carotid intima media thickness (cIMT), and ankle brachial index (ABI). We conducted a cross-sectional case-control study of 54 patients with acromegaly (37 females and 17 males) and 34 healthy controls (22 females and 12 males). Serum visfatin was measured by ELISA. Acromegalic and control participants and those with active or controlled acromegaly were compared with respect to their serum visfatin, clinical and metabolic parameters, EFT, cIMT, and ABI. Linear correlation was used to identify associations between these parameters and visfatin in all participants. Serum visfatin and glycated hemoglobin (HbA1c) were higher in the acromegaly group than in the control group (p<0.001 and p=0.007, respectively). There was no difference in visfatin between the active and controlled acromegaly groups, but HbA1c was higher in the active than the controlled acromegaly group (p<0.04). EFT, cIMT, and ABI were similar between the acromegaly and control groups and between the active and controlled acromegaly groups. Serum visfatin positively correlated with HbA1c, growth hormone (GH), and insulin-like growth factor-1 (IGF-1)/upper limit of normal ratio (r=0.245, p=0.024; r=0.259, p=0.017; and r=0.282, p=0.009, respectively). This study has revealed that a high visfatin level is associated with glycemic dysregulation and higher levels of GH and IGF-1 in acromegalic patients.

Key words

visfatin - acromegaly - diabetes mellitus - epicardial fat thickness - carotid intima media thickness

Volltext

Referenzen

References
1 Katznelson L, Laws Jr. ER, Melmed S. et al. Endocrine Society. Acromegaly: An endocrine society clinical practice guideline. J Clin Endocrinol Metab 2014; 99: 3933-3951
2 Melmed S, Casanueva FF, Klibanski A. et al. A consensus on the diagnosis and treatment of acromegaly complications. Pituitary 2013; 16: 294-302
3 Møller N, Jørgensen JO. Effects of growth hormone on glucose, lipid, and protein metabolism in human subjects. Endocr Rev 2009; 30: 152-177
4 Frara S, Maffezzoni F, Mazziotti G. et al. Current and emerging aspects of diabetes mellitus in acromegaly. Trends Endocrinol Metab 2016; 27: 470-483
5 Dogansen SC, Yalin GY, Tanrikulu S. et al. Impact of glucose metabolism disorders on IGF-1 levels in patients with acromegaly. Horm Metab Res 2018; 50: 408-413
6 Mercado M, Ramírez-Rentería C. Metabolic complications of acromegaly. Front Horm Res 2018; 49: 20-28
7 Ritvonen E, Löyttyniemi E, Jaatinen P. et al. Mortality in acromegaly: A 20-year follow-up study. Endocr Relat Cancer 2016; 23: 469-480
8 Olarescu NC, Bollerslev J. The impact of adipose tissue on IR in acromegaly. Trends Endocrinol Metab 2016; 27: 226-237
9 Kershaw EE, Flier JS. Adipose tissue as an endocrine organ. J Clin Endocrinol Metab 2004; 89: 2548-2556
10 Fukuhara A, Matsuda M, Nishizawa M. et al. Visfatin: a protein secreted by visceral fat that Mimics the effects of insulin. Science 2005; 307: 426-430
11 Uzun G, Ozden S. Visfatin and its effects. Journal of Turkish Clinical Biochemistry 2013; 11: 119-130
12 Sucunza N, Barahona MJ, Resmini E. et al. A link between bone mineral density and serum adiponectin and visfatin levels in acromegaly. J Clin Endocrinol Metab 2009; 94: 3889-3896
13 Olarescu NC, Ueland T, Lekva T. et al. Adipocytes as a source of increased circulating levels of nicotinamide phosphoribosyltransferase/visfatin in active acromegaly. J Clin Endocrinol Metab 2012; 97: 1355-1362
14 Ciresi A, Amato MC, Pizzolanti G. et al. Serum visfatin levels in acromegaly: Correlation with disease activity and metabolic alterations. Growth Horm IGF Res 2015; 25: 240-246
15 Cansu GB, Yılmaz N, Yanıkoğlu A. et al. Assessment of diastolic dysfunction, arterial stiffness, and carotid intima-media thickness in patients with acromegaly. Endocr Pract 2017; 23: 536-545
16 Ozkan C, Altinova AE, Cerit ET. et al. Markers of early atherosclerosis, oxidative stress and inflammation in patients with acromegaly. Pituitary 2015; 18: 621-629
17 World Health Organization. Physical Status: The use and interpretation of anthropometry. Report of a WHO Expert Committee. World Health Organ Tech Rep Ser 1995; 854: 1-452
18 American Diabetes Association. Standarts of medical care in in diabetes. Classification and diagnosis of diabetes mellitus. Diabetes Care 2016; 39: 13-23
19 Matthews DR, Hosker JP, Rudenski AS. et al. Homeostasis model assessment: IR and beta-cell function from fasting plasma glucose and insulin concentrations in man. Diabetologia 1985; 28: 412-419
20 Iacobellis G, Ribaudo MC, Assael F. et al. Echocardio-graphic epicardial adipose tissue is related to anthropometricand clinical parameters of metabolic syndrome: A new indicatorof cardiovascular risk. J Clin Endocrinol Metab 2003; 88: 5163-5168
21 Fowkes FG, Murray GD, Butcher I. et al. Ankle brachial index combined with Framingham Risk Score to predict cardio-vascular events and mortality: A meta-analysis. JAMA 2008; 300: 197-208
22 Giustina A, Chanson P, Bronstein MD. et al. Acromegaly Consensus Group A consensus on criteria for cure of acromegaly. J Clin Endocrinol Metab 2010; 95: 3141-3148
23 Goodman HM. Multiple effects of growth hormone on lipolysis. Endocrinology 1968; 83: 300-308
24 Freda PU, Shen W, Heymsfield SB. et al. Lower visceral and subcutaneous but higher intermuscular adipose tissue depots in patients with growth hormone and insulin-like growth fact or I excess due to acromegaly. J Clin Endocrinol Metab 2008; 93: 2334-2343
25 Ciresi A, Amato MC, Pivonello R. et al. The metabolic profile in active acromegaly is gender-specific. J Clin Endocrinol Metab 2013; 98: 51-59
26 Moschen AR, Kaser A, Enrich B. et al. Visfatin, an adipocytokine with proinflammatory and immunomodulating properties. J Immunol 2007; 178: 1748-1758
27 Dahl TB, Yndestad A, Skjelland M. et al. Increased expression of visfatin in macrophages of human unstable carotid and coronary atherosclerosis: Possible role in inflammation and plaque destabilization. Circulation 2007; 115: 972-980
28 Chen MP, Chung FM, Chang DM. et al. Elevated plasma level of visfatin/pre-B cell colony-enhancing factor in patients with type 2 diabetes mellitus. J Clin Endocrinol Metab 2006; 91: 295-299
29 Lopez-Bermejo A, Chico-Julia B, Fernandez-Balsells M. et al. Serum visfatin increases with progressive beta-cell deterioration. Diabetes 2006; 55: 2871-2875
30 Li L, Yang G, Li Q. et al. Changes and relations ofcirculating visfatin, apelin, and resistin levels in normal, impaired glucose tolerance, and type 2 diabetic subjects. Exp Clin Endocrinol Diabetes 2006; 114: 544-548
31 Gunduz FO, Yildirmak ST, Temizel M. et al. Serum visfatin and fetuin-A levels and glycemic control in patients with obese type 2 diabetes mellitus. Diabetes Metab J 2011; 35: 523-538
32 Taskesen D, Kirel B, Us T. Serum visfatin levels, adiposity and glucose metabolism in obese adolescents. J Clin Res Pediatr Endocrinol 2012; 4: 76-81
33 Olszanecka-Glinianowicz M, Owczarek A, Bożentowicz-Wikarek M. et al. Relationship between circulating visfatin/NAMPT, nutritional status and IR in an elderly population - results from the PolSenior substudy. Metabolism 2014; 63: 1409-1418
34 Dogru T, Sonmez A, Tasci I. et al. Plasma visfatin levels in patients with newly diagnosed and untreated type 2 diabetes mellitus and impaired glucose tolerance. Diabetes Res Clin Pract 2007; 76: 24-29
35 Turgut S, Topsakal S, Ata MT. et al. Leptin receptor gene polymorphism may affect subclinical atherosclerosis in patients with acromegaly. Avicenna J Med Biotech 2016; 8: 145-150
36 Topsakal S, Akin F, Turgut S. et al. Relationship of apelin, procalcitonin, and fetuin-A concentrations with carotid intima-media thickness in acromegaly. Ann Clin Biochem 2015; 52: 456-461